medicationPrescription only (US)
MetoprololBenefits, Dosage & Interactions
Metoprolol is a prescription medication belonging to a class of drugs called beta-blockers. Specifically, it is a cardioselective beta-1 adrenergic blocker, meaning it primarily affects beta-1 receptors in the heart. It is typically taken in the morning. The reported plasma half-life is about 3.5 hours, which shapes dosing frequency.
How much Metoprolol do people take?
The cited randomized trial titrated metoprolol CR/XL up to a target of 200 mg once daily in chronic heart failure. Route reported: Oral. Frequency reported: Once daily (extended-release) in the cited trial. These are amounts documented in the cited studies and labels for Metoprolol — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Moderate — One published human randomized trial; results not yet replicated.
Evidence strengthModerate · 3/4
PreclinicalStrong human evidence
One published human randomized trial; results not yet replicated.
Plasma half-life
~3.5 h
Typical timing
in the morning
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- The cited randomized trial titrated metoprolol CR/XL up to a target of 200 mg once daily in chronic heart failure[1]
- Route studied
- Oral[1]
- Frequency
- Once daily (extended-release) in the cited trial[1]
- Cycle length
- Trial stopped early at a mean follow-up of about 1 year for a mortality benefit[1]
- Half-life
- Roughly 3-7 hours (immediate-release)[1]
- Storage
- Room temperature, sealed[1]
Reported for Metoprolol in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Metoprolol entry is written from. Each number matches an inline marker above.
- [1]Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)MERIT-HF Study Group · Lancet · 1999 · Peer-reviewed · PMID 10376614
References & Evidence
Sources on this page that document Metoprolol dosing, timing and safety.
- [1]U.S. National Library of Medicine View source
- [2]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Metoprolol?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Metoprolol is a prescription medication belonging to a class of drugs called beta-blockers. Specifically, it is a cardioselective beta-1 adrenergic blocker, meaning it primarily affects beta-1 receptors in the heart. Metoprolol is commonly prescribed to manage various cardiovascular conditions, including hypertension (high blood pressure), angina pectoris (chest pain), and to improve survival after a heart attack (myocardial infarction). It is also used to treat certain heart rhythm disorders and can be part of the treatment regimen for heart failure. Metoprolol is available in two main forms: metoprolol tartrate (immediate-release) and metoprolol succinate (extended-release). The extended-release formulation often allows for once-daily dosing, which can improve patient adherence. As a controlled medication, the dosage for Metoprolol must be set by a licensed clinician. (FDA label, DrugBank)
What does the research say about Metoprolol?
Tap a section to expand.
Metoprolol works by selectively blocking beta-1 adrenergic receptors, primarily located in the heart. When these receptors are blocked, the effects of epinephrine (adrenaline) and norepinephrine on the heart are reduced. This reduction leads to several physiological changes beneficial in cardiovascular conditions. Metoprolol decreases heart rate, reduces the force of heart muscle contraction, and lowers cardiac output. By reducing the heart's workload, it also decreases myocardial oxygen demand, which is beneficial for conditions like angina. Furthermore, beta-blockers like metoprolol can inhibit the release of renin from the kidneys, contributing to its blood pressure-lowering effects. The precise mechanisms by which metoprolol improves survival post-myocardial infarction and in heart failure are complex but involve reducing sympathetic nervous system overactivity and protecting the heart from detrimental remodeling. (DrugBank, EMA SmPC)
Source for this section: Sources for How does Metoprolol work?: Jumps to this entry in the sources and references list at the end of the page.
Metoprolol offers several established benefits for patients with various cardiovascular conditions:
* **Hypertension (High Blood Pressure):** It effectively lowers blood pressure, reducing the risk of complications such as stroke, heart attack, and kidney disease. (NIH ODS)
* **Angina Pectoris (Chest Pain):** By decreasing heart rate and myocardial oxygen demand, metoprolol can reduce the frequency and severity of angina attacks, improving exercise tolerance. (Mayo Clinic)
* **Myocardial Infarction (Heart Attack):** Administered after a heart attack, metoprolol can improve long-term survival and reduce the risk of future cardiovascular events. (NIH ODS)
* **Heart Failure:** In stable, chronic heart failure, metoprolol succinate (extended-release) is proven to reduce mortality and hospitalizations, improving quality of life. (Cochrane, FDA label)
* **Certain Arrhythmias:** It can be used to control the ventricular rate in conditions like atrial fibrillation and atrial flutter. (MedlinePlus)
Numerous large-scale clinical trials and meta-analyses support the efficacy of metoprolol in its approved indications. For hypertension, metoprolol's effectiveness in lowering blood pressure and reducing cardiovascular events is well-documented in numerous studies and guidelines. In the treatment of angina, studies have consistently shown its ability to decrease anginal episodes and improve exercise capacity. The benefit of metoprolol in improving survival post-myocardial infarction has been demonstrated in landmark trials such as the METOCARD-C and the MIAMI trials, showing significant reductions in mortality. For chronic heart failure, the MERIT-HF trial (Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure) was a pivotal study demonstrating that metoprolol succinate significantly reduced all-cause mortality and hospitalizations in patients with stable, chronic heart failure. The findings from these trials are widely cited and form the basis for current treatment guidelines by organizations such as the American Heart Association and the European Society of Cardiology. (Cochrane, PubChem, DrugBank)
Like all medications, metoprolol can cause side effects. Common side effects often include fatigue, dizziness, lightheadedness, nausea, slow heart rate (bradycardia), and cold hands and feet. Some individuals may experience diarrhea or constipation. More serious, though less common, side effects can include shortness of breath, wheezing, significant drops in blood pressure, depression, visual disturbances, and allergic reactions (rash, itching, swelling). Patients with diabetes should be aware that metoprolol can mask the symptoms of low blood sugar, such as a rapid heartbeat. It can also worsen symptoms in some individuals with asthma or chronic obstructive pulmonary disease (COPD). It is crucial to report any concerning side effects to a healthcare provider. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for What are the side effects of Metoprolol?: Jumps to this entry in the sources and references list at the end of the page.
Metoprolol carries several important warnings. Abrupt discontinuation of metoprolol can exacerbate angina, lead to myocardial infarction, or result in ventricular arrhythmias in patients with coronary artery disease, necessitating gradual tapering under medical supervision. It should be used with caution in patients with bronchospastic diseases (e.g., asthma, COPD) as it can worsen airway obstruction. In patients with diabetes, metoprolol can mask symptoms of hypoglycemia, such as tachycardia, and may affect glucose metabolism. Patients with peripheral vascular disease may experience worsened symptoms. Metoprolol should be used cautiously in patients with certain heart rhythm problems (e.g., severe bradycardia, sick sinus syndrome without a pacemaker, second or third-degree AV block) as it can further slow heart rate. It should also be used with care in patients with pheochromocytoma (typically with an alpha-blocker concomitantly) and hyperthyroidism, as it can mask symptoms of thyrotoxicosis and abrupt withdrawal could precipitate thyroid storm. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for Who should avoid Metoprolol?: Jumps to this entry in the sources and references list at the end of the page.
Metoprolol is contraindicated in certain situations. These include severe bradycardia (heart rate less than 45 beats per minute), second or third-degree atrioventricular (AV) block (unless a permanent pacemaker is in place), decompensated heart failure requiring intravenous inotropic therapy, cardiogenic shock, and sick sinus syndrome (unless a permanent pacemaker is in place). It is also contraindicated in patients with severe peripheral arterial circulatory disorders, and in individuals with a known hypersensitivity to metoprolol or other beta-blockers, or to any component of the formulation. (FDA label, EMA SmPC). This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for When should Metoprolol not be taken?: Jumps to this entry in the sources and references list at the end of the page.
Mixing metoprolol with certain other medications can lead to adverse interactions.
* **Calcium Channel Blockers (e.g., verapamil, diltiazem):** Concomitant use can significantly increase the risk of bradycardia, AV block, and hypotension.
* **Other Antihypertensives:** Co-administration with other blood pressure-lowering agents (e.g., ACE inhibitors, ARBs, diuretics) can lead to additive hypotensive effects.
* **Clonidine:** If clonidine is discontinued while on metoprolol, a rebound hypertension crisis may occur. If both are stopped, clonidine should be tapered first.
* **Digitalis Glycosides (e.g., digoxin):** Both can slow heart rate and AV conduction, increasing the risk of bradycardia and heart block.
* **MAO Inhibitors:** Risk of significant hypertension or bradycardia.
* **Certain Antidepressants (e.g., SSRIs):** Some antidepressants can inhibit metoprolol metabolism, increasing its blood levels and potential for side effects.
* **CYP2D6 Inhibitors (e.g., quinidine, fluoxetine, paroxetine, propafenone):** These drugs can significantly increase metoprolol plasma concentrations, leading to increased beta-blocking effects.
* **Nonsteroidal Anti-inflammatory Drugs (NSAIDs):** NSAIDs may reduce the antihypertensive effect of beta-blockers.
* **Alcohol:** Can enhance the hypotensive effect and may increase CNS depressive effects.
Always inform your healthcare provider about all medications, supplements, and herbal products you are taking. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for What should you not mix with Metoprolol?: Jumps to this entry in the sources and references list at the end of the page.
Metoprolol is typically taken in the morning. Metoprolol tartrate (immediate-release) is usually taken twice daily, often with or immediately after meals to improve absorption and reduce gastric upset. Metoprolol succinate (extended-release) is typically taken once daily, usually in the morning, and can be taken with or without food, though taking it consistently with food may help maintain steady drug levels. Adherence to a consistent dosing schedule, as directed by a healthcare provider, is important for maintaining stable blood pressure and heart rate control. Always follow the specific instructions provided by your prescribing clinician regarding the timing and administration of your metoprolol formulation.
Source for this section: Sources for When should you take Metoprolol?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Metoprolol is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Metoprolol?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Specific pairs are checked against a licensed source; confirm with your provider. |
| Amantadine | Caution | Compound pairConfidence: theoretical | Both drugs can lower heart rate and blood pressure. Combining raises risk of bradycardia, dizziness, and falls.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Check pulse and BP at home. Report a resting pulse under 55 or dizziness. |
Frequently asked questions about Metoprolol
Metoprolol tartrate is an immediate-release formulation, typically taken twice daily. Metoprolol succinate is an extended-release (ER) formulation, which allows for once-daily dosing. The extended-release form provides more consistent blood levels over 24 hours, often preferred for chronic conditions like heart failure and hypertension management.
No, you should not suddenly stop taking metoprolol. Abruptly discontinuing metoprolol, especially in patients with heart disease, can lead to serious adverse events such as worsening chest pain, heart attack, or dangerous heart rhythm problems. If you need to stop the medication, your doctor will likely guide you through a gradual tapering process over several weeks.
Yes, metoprolol can affect blood sugar. In diabetic patients, it can mask the symptoms of low blood sugar (hypoglycemia), such as a rapid heart rate, making it harder to recognize when blood sugar levels are too low. It can also potentially alter glucose metabolism. Patients with diabetes should monitor their blood sugar carefully when taking metoprolol and discuss any concerns with their doctor.
Weight gain is reported as a potential side effect of beta-blockers, including metoprolol, for some individuals. While the exact mechanism is not fully understood, it may be related to changes in metabolism or activity levels. However, it's not a universal side effect, and many people do not experience significant weight changes. If you are concerned about weight gain, discuss it with your healthcare provider.
Metoprolol is generally considered in Pregnancy Category C, meaning animal studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Your doctor will weigh the risks and benefits carefully and consider alternatives if necessary. Always consult your obstetrician or prescribing clinician.
Interaction risk for Metoprolol comes from the rest of the stack: other medications, prescription medicines, hormone therapy and peptides. Because Metoprolol is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 3.5 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Metoprolol with no sign-up.
Metoprolol is typically taken in the morning. The reported plasma half-life is about 3.5 hours, which is what drives how often it is redosed. It is a controlled substance in some jurisdictions, so the prescribed amount is the only appropriate one. Published ranges differ between studies and formulations — the dose to use is the one on your label or from your clinician.
There is no single answer for Metoprolol plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing Metoprolol with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A short plasma half-life of roughly 3.5 hours is why protocols often split Metoprolol across the day rather than using a single dose. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
Because Metoprolol clears quickly (plasma half-life around 3.5 hours), a missed dose leaves a real gap in exposure rather than being buffered by what is still in your system. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Metoprolol the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
The cited randomized trial titrated metoprolol CR/XL up to a target of 200 mg once daily in chronic heart failure. Route reported: Oral. Frequency reported: Once daily (extended-release) in the cited trial. These are amounts documented in the cited studies and labels for Metoprolol — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Metoprolol?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Clinical Pharmacokinetics of Metoprolol: A Systematic Review(opens PubMed in a new tab)Clin Pharmacokinet · 2022 · PMID 35764772 · https://pubmed.ncbi.nlm.nih.gov/35764772/
- 2.Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial(opens PubMed in a new tab)Lancet · 2003 · PMID 12853193 · https://pubmed.ncbi.nlm.nih.gov/12853193/
- 3.Metoprolol for the Prevention of Acute Exacerbations of COPD(opens PubMed in a new tab)N Engl J Med · 2019 · PMID 31633896 · https://pubmed.ncbi.nlm.nih.gov/31633896/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- MedlinePlus(opens in a new tab)U.S. National Library of Medicine · medlineplus.gov/druginfo/meds/a682864.html
- PubChem CID 6440651(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/6440651
Verify at
Publisher search links for Metoprolol. These are places to check the information — they are not citations, so they are not numbered.
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- European Medicines Agency(publisher search, opens in a new tab)European Medicines Agency · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Metoprolol?
Plain-text summary, safe to quote verbatim:
Metoprolol is a prescription medication belonging to a class of drugs called beta-blockers. Specifically, it is a cardioselective beta-1 adrenergic blocker, meaning it primarily affects beta-1 receptors in the heart. It is typically taken in the morning. The reported plasma half-life is about 3.5 hours, which shapes dosing frequency.
Source: DoseRoutine — https://doseroutine.com/library/metoprolol
Metoprolol cheat sheet
DoseRoutine cheat sheet · Medication
Metoprolol
Metoprolol is a prescription medication belonging to a class of drugs called beta-blockers. Specifically, it is a cardioselective beta-1 adrenergic blocker, meaning it primarily affects beta-1 receptors in the heart.
Evidence
Moderate
One published human randomized trial; results not yet replicated.
Studied range
The cited randomized trial titrated metoprolol CR/XL up to a target of 200 mg once daily in chronic heart failure
Route
Oral
Frequency studied
Once daily (extended-release) in the cited trial
Half-life
~3.5 h
Timing
in the morning
Storage
Room temperature, sealed
Prescription only (US)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/metoprolol
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Metoprolol — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/metoprolol
What compounds are similar to Metoprolol?
Others in the medication category or studied for the same goals.